Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer

BACKGROUND: Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with endocrine therapy. Emerging real-life data suggest that the efficacy of a palbociclib-based therapy is highly conserved. We report the In...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast
Main Authors: Porte, B., Carton, M., Lerebours, F., Brain, E., Loirat, D., Haroun, L., Bellesoeur, A., Bach Hamba, S., Kirova, Y., Cottu, P.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7695984/
https://ncbi.nlm.nih.gov/pubmed/33242757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.11.008
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares